Forodesine is approved in Japan for the treatment of PTCL and exhibits antitumor activity in a subset of patients, but it is unclear whether tumor cell lethality or TLR7 agonism underlies this effect (44). The gene discussed is TLR7; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.